Sigyn Therapeutics, Inc. Quarterly report pursuant to Section 13 or 15(d)

Quarterly report pursuant to Section 13 or 15(d)

EARNINGS PER SHARE

EARNINGS PER SHARE

9 Months Ended

Sep. 30, 2018

NOTE 13 – EARNINGS PER SHARE

FASB ASC Topic 260, Earnings Per Share, requires a reconciliation of the numerator and denominator of the basic and diluted earnings (loss) per share (EPS) computations.

Basic earnings (loss) per share are computed by dividing net earnings available to common shareholders by the weighted-average number of common shares outstanding during the period. Diluted earnings (loss) per share is computed similar to basic earnings per share except that the denominator is increased to include the number of additional common shares that would have been outstanding if the potential common shares had been issued and if the additional common shares were dilutive. In periods where losses are reported, the weighted-average number of common stock outstanding excludes common stock equivalents, because their inclusion would be anti-dilutive.

Basic and diluted earnings (loss) per share are the same since the Company had net losses for all periods presented and including the additional potential common shares would have an anti-dilutive effect.

The following table sets forth the computation of basic and diluted net income per share:

	For the Nine Months Ended September 30,						For the Three Months Ended September 30,
	2018			2017			2018			2017
Net loss attributable to the common stockholders	$	(1,402,686	)	$	(3,076,017	)	$	(355,987	)	$	(1,497,699	)

Basic weighted average outstanding shares of common stock		61,710,263			45,372,823			65,460,451			48,034,278
Dilutive effect of options and warrants		—			—			—			—
Diluted weighted average common stock and common stock equivalents		61,710,263			45,372,823			65,460,451			48,034,278

Loss per share:
Basic and diluted	$	(0.02	)	$	(0.07	)	$	(0.01	)	$	(0.03	)